Accuray (ARAY): CFO Meeting Takeaways - Jefferies

September 27, 2016 8:16 AM EDT
Get Alerts ARAY Hot Sheet
Price: $5.20 +1.96%

Rating Summary:
    7 Buy, 4 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 19 | Down: 19 | New: 13
Trade ARAY Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies analyst, Anthony Petrone, reiterated his Buy rating on shares of Accuray (NASDAQ: ARAY) after meeting with CFO, Kevin Waters.

Key takeaways included: 1) New Radixact System unveiled to high interest

2) Company making strides to close treatment planning gap

3) Base retention still high and supported by Radixact going forward

4) Launch timing supports back-half bookings acceleration

5) 5-year SBRT prostate shows significant survival benefit further supporting transition toward hypofraction.

No change to the price target of $8.00

For an analyst ratings summary and ratings history on Accuray click here. For more ratings news on Accuray click here.

Shares of Accuray closed at $5.53 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Management Comments

Related Entities

Jefferies & Co

Add Your Comment